Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature

The three different botulinum toxin type A (BoNT/A) preparations being licensed in Europe and the U.S. differ in protein content, which seems to be a major factor influencing the antigenicity of BoNT/A. In the present study, several arguments out of our research pool were collected to demonstrate th...

Full description

Bibliographic Details
Main Authors: Sara Samadzadeh, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, John-Ih Lee, Philipp Albrecht, Harald Hefter
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Toxins
Subjects:
low antigenicity
incobotulinum toxin
neutralizing antibodies
secondary treatment failure
complex proteins: botulinum toxin type A
cervical dystonia
Online Access:https://www.mdpi.com/2072-6651/12/8/499

Internet

https://www.mdpi.com/2072-6651/12/8/499

Similar Items